OMGA News and Press, Omega Therapeutics Inc. From 07/12/23

CAMBRIDGE, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the appointment of Chris Schade to its B...

REDWOOD CITY, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of inflammation, today announced th...

MYC-targeting Omega Epigenomic Controllers (OECs) Demonstrated Consistent Anti-Tumor Activity Across Multiple Tumor Types, Including Hepatocellular Carcinoma and Non-Small Cell Lung Cancer, in Preclinical Models MYC OECs Modulate Tumor Microenvironment, Enhanced Response to Checkpoint...

Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry PR Newswire The company's MIMiC™ platform drives unprecedented insights into molecular interactions to design new biomolecules precisely tuned for therapeutic benefi...

2023-05-10 15:28:29 ET Summary Among US-listed biotech stocks with promising prospects, investors should consider holding a position in Omega Therapeutics, Inc. as the company calls 2023 a pivotal year. Omega Therapeutics is a clinical-stage developer of controllers of the epigene...

2023-05-04 10:42:27 ET Omega Therapeutics press release ( NASDAQ: OMGA ): Q1 GAAP EPS of -$0.50 beats by $0.13 . Revenue of $0.52M (+92.6% Y/Y) beats by $0.21M . For further details see: Omega Therapeutics GAAP EPS of -$0.50 beats by $0.13, revenue of $0....

Continued to Advance Monotherapy Dose Escalation Stage of Ongoing Phase 1/2 MYCHELANGELO™ I Study; Preliminary Data Anticipated in 2023 Announced Clinical Supply Agreement with Roche to Evaluate OTX-2002 in Combination with Atezolizumab in MYCHELANGELO I Study Advanced Othe...

CAMBRIDGE, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that it will present new preclinical da...

2023-04-05 13:14:41 ET Gainers: Nuburu ( BURU ) +83% . Liminal BioSciences ( LMNL ) +80% . InflaRx ( IFRX ) +75% . 180 Life Sciences ( ATNF ) +38% . Freight Technologies ( FRGT ) +25% . Omega Therapeutics ( OMGA ) +23% ...

CAMBRIDGE, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenetic mRNA medicines, today announced a clinical supply agreement with Roche ...